Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
C 195.1 -2.68% -5.37
UTHR closed down 2.68 percent on Friday, September 24, 2021, on 77 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical UTHR trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -2.68%
Multiple of Ten Bullish Other -2.68%
Oversold Stochastic Weakness -2.68%
Older End-of-Day Signals for UTHR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

United Therapeutics Corporation Description

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Organic Compounds Hypertension Blastoma Alcohols Pulmonary Arterial Hypertension Hepatitis C Pulmonary Hypertension Brain Cancer Neuroblastoma Lung Diseases Treprostinil Chronic And Life Threatening Conditions Prostacyclin Prostaglandins

Is UTHR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 216.9
52 Week Low 100.05
Average Volume 275,526
200-Day Moving Average 181.78
50-Day Moving Average 200.05
20-Day Moving Average 206.74
10-Day Moving Average 202.24
Average True Range 4.77
ADX 22.93
+DI 14.60
-DI 29.59
Chandelier Exit (Long, 3 ATRs) 202.20
Chandelier Exit (Short, 3 ATRs) 208.82
Upper Bollinger Bands 217.94
Lower Bollinger Band 195.53
Percent B (%b) -0.02
BandWidth 10.84
MACD Line -1.02
MACD Signal Line 0.85
MACD Histogram -1.8625
Fundamentals Value
Market Cap 8.67 Billion
Num Shares 44.4 Million
EPS 10.59
Price-to-Earnings (P/E) Ratio 18.42
Price-to-Sales 4.08
Price-to-Book 1.76
PEG Ratio 7.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 203.40
Resistance 3 (R3) 204.12 202.09 202.01
Resistance 2 (R2) 202.09 199.97 201.72 201.55
Resistance 1 (R1) 198.59 198.67 197.58 197.87 201.09
Pivot Point 196.56 196.56 196.05 196.19 196.56
Support 1 (S1) 193.06 194.44 192.05 192.34 189.11
Support 2 (S2) 191.03 193.14 190.66 188.65
Support 3 (S3) 187.53 191.03 188.19
Support 4 (S4) 186.81